February 27, 2024
2 min watch
Save
VIDEO: Nab-paclitaxel shows promise for treatment of neuroendocrine tumors
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Laleh Melstrom, MD, MS, discusses results from the NABNEC study, a randomized phase 2 study of nab-paclitaxel in combination with carboplatin as first-line treatment of gastrointestinal neuroendocrine carcinomas.
The experimental arm had higher response rates than the control arm, Melstrom, a surgical oncologist at City of Hope, said of the study presented at ASCO Gastrointestinal Cancers Symposium.
Melstrom also noted a 24-month overall survival of 25% in the experimental group compared with 17% in the control.
"There is a signal with nab-paclitaxel — this may be an option for patients that may not be candidates for etoposide," said Melstrom.
Reference:
- Chantrill L, et al. Abstract 589. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Melstrom reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.